GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
Subscribe To Our Newsletter & Stay Updated
